Lv3
262 积分 2025-05-06 加入
CAR T-cell therapy for secondary CNS DLBCL
1天前
待确认
Early Use of Tocilizumab Following Cytokine Release Syndrome During CAR-T Therapy for Multiple Myeloma May Be Associated With Fewer Short and Long Term Adverse Cardiovascular Events
1个月前
已关闭
Clinical Outcomes in Relapsed DLBCL Patients Approved for CAR-T Therapy-A Single-Centre Study
2个月前
已完结
Impact of Baseline Anxiety and Depression on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
2个月前
已完结
CLINICAL BIOMARKERS ASSOCIATED with PROGRESSION FREE SURVIVAL to CILTACABTAGENE AUTOLEUCEL in CHINESE PATIENTS with RELAPSED/REFRACTORY MULTIPLE MYELOMA from CARTIFAN-1 STUDY
2个月前
已关闭
ENHANCED CAR T-CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR-255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
2个月前
已关闭
Impact of Pre-Existing Neurocognitive Impairments on Toxicity and Outcomes after Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisangenleucel for Patients with Diffuse Large B-cell Lymphoma
2个月前
已关闭
皖公网安备34019202002308
